UL Stock Analysis: Unilever | NYSE
Household & Personal Products | NYSE, USA | Market Cap: 134.532m USD | 12M Return: -6.2% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 228M
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Unilever PLC is a global fast-moving consumer goods (FMCG) company headquartered in London, with operations spanning Asia Pacific, Africa, the Americas, and Europe. The business is organized into four segments: Beauty & Wellbeing, Personal Care, Home Care, and Foods, covering categories such as hair and skin care, deodorants and oral care, laundry and household cleaning products, and cooking aids and condiments. Unilever sells its products under a broad portfolio of well-known brands, including Dove, Hellmanns, Knorr, Vaseline, TRESemmé, Sunsilk, and Ponds, among others. Founded in 1860, the company has built a global presence through a multi-brand, multi-category strategy that targets both mass-market consumers and prestige segments such as Dermalogica, Paulas Choice, and Nutrafol.
As an FMCG operator, Unilevers business model is built on high-volume, frequently replenished product categories that generate relatively predictable, recurring revenue streams, which is typical of the consumer staples sector. The companys segment structure reflects a deliberate balance between personal consumption categories (beauty and personal care), household essentials (home care), and food products, allowing it to diversify demand cycles across geographies and consumer spending patterns.
- Prestige Beauty brands accelerate Beauty and Wellbeing growth
- Ice cream demerger sharpens portfolio and margin focus
- Emerging market FX headwinds pressure reported revenue
| Net Income: 6.08b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 0.27 > 1.0 |
| NWC/Revenue: -9.12% < 20% (prev -9.94%; Δ 0.82% < -1%) |
| CFO/TA 0.12 > 3% & CFO 8.52b > Net Income 6.08b |
| Net Debt (27.0b) to EBITDA (11.1b): 2.43 < 3 |
| Current Ratio: 0.79 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.20b) vs 12m ago -13.16% < -2% |
| Gross Margin: 46.79% > 18% (prev 45.05%; Δ 1.74% > 0.5%) |
| Asset Turnover: 67.05% > 50% (prev 76.19%; Δ -9.14% > 0%) |
| Interest Coverage Ratio: 11.71 > 6 (EBIT TTM 9.85b / Interest Expense TTM 841.5m) |
| A: -0.07 (Total Current Assets 17.1b - Total Current Liabilities 21.7b) / Total Assets 70.4b |
| B: 0.63 (Retained Earnings 44.2b / Total Assets 70.4b) |
| C: 0.13 (EBIT TTM 9.85b / Avg Total Assets 75.1b) |
| D: 0.29 (Book Value of Equity 15.5b / Total Liabilities 52.9b) |
| Altman-Z'' = 2.81 = A |
| DSRI: 1.81 (Receivables 7.67b/5.12b, Revenue 50.4b/60.8b) |
| GMI: 0.96 (GM 45.05% / 46.79%) |
| AQI: 1.03 (AQ_t 0.63 / AQ_t-1 0.61) |
| SGI: 0.83 (Revenue 50.4b / 60.8b) |
| TATA: -0.03 (NI 6.08b - CFO 8.52b) / TA 70.4b) |
| Beneish M = -2.50 (Cap -4..+1) = A |
As of July 08, 2026, the stock is trading at USD 62.74 with a total of 2,309,275 shares traded. Over the past week, the price has changed by +2.52%, over one month by +11.86%, over three months by +13.72% and over the past year by -6.19%.
Current recommended Stop Loss: 60.30 (which is 3.9% or 2.3 ATR below the current price).
Unilever has received a consensus analysts rating of 4.40. Therefore, it is recommended to buy UL.
- StrongBuy: 3
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 68.2 | 8.7% |
Market Cap EUR = 118b (135b USD * 0.8764 USD.EUR)
P/E Trailing = 21.1797
P/E Forward = 17.6056
P/S = 2.6638
P/B = 7.6069
P/EG = 11.7421
Revenue TTM = 50.4b EUR
EBIT TTM = 9.85b EUR
EBITDA TTM = 11.1b EUR
Long Term Debt = 25.7b EUR (from longTermDebt, last quarter)
Short Term Debt = 2.58b EUR (from shortTermDebt, last quarter)
Debt = 30.9b EUR (from shortLongTermDebtTotal, last quarter) + Leases 1.33b
Net Debt = 27.0b EUR (calculated: Debt 30.9b - CCE 3.94b)
Enterprise Value = 145b EUR (118b + Debt 30.9b - CCE 3.94b)
Interest Coverage Ratio = 11.71 (Ebit TTM 9.85b / Interest Expense TTM 841.5m)
EV/FCF = 20.51x (Enterprise Value 145b / FCF TTM 7.06b)
FCF Yield = 4.87% (FCF TTM 7.06b / Enterprise Value 145b)
FCF Margin = 14.03% (FCF TTM 7.06b / Revenue TTM 50.4b)
Net Margin = 12.07% (Net Income TTM 6.08b / Revenue TTM 50.4b)
Gross Margin = 46.79% ((Revenue TTM 50.4b - Cost of Revenue TTM 26.8b) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 2.06 (Enterprise Value 145b / Total Assets 70.4b)
Interest Expense / Debt = 2.72% (Interest Expense 841.5m / Debt 30.9b)
Taxrate = 28.52% (2.47b / 8.67b)
NOPAT = 7.04b (EBIT 9.85b * (1 - 28.52%))
Current Ratio = 0.79 (Total Current Assets 17.1b / Total Current Liabilities 21.7b)
Debt / Equity = 1.99 (Debt 30.9b / totalStockholderEquity, last quarter 15.5b)
Debt / EBITDA = 2.43 (Net Debt 27.0b / EBITDA 11.1b)
Debt / FCF = 3.82 (Net Debt 27.0b / FCF TTM 7.06b)
Total Stockholder Equity = 18.4b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.09% (Net Income 6.08b / Total Assets 70.4b)
RoE = 33.02% (Net Income TTM 6.08b / Total Stockholder Equity 18.4b)
RoCE = 22.34% (EBIT 9.85b / Capital Employed (Equity 18.4b + L.T.Debt 25.7b))
RoIC = 14.42% (NOPAT 7.04b / Invested Capital 48.9b)
WACC = 4.81% (E(118b)/V(149b) * Re(5.56%) + D(30.9b)/V(149b) * Rd(2.72%) * (1-Tc(0.29)))
Discount Rate = 5.56% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -93.21 | Cagr: -6.50%
[DCF] Terminal Value 74.08% ; FCFF base≈7.35b ; Y1≈6.81b ; Y5≈6.14b
[DCF] Fair Price = 32.61 (EV 97.2b - Net Debt 27.0b = Equity 70.2b / Shares 2.15b; r=8.35% [WACC [floored]]; 5y FCF grow -9.23% → 2.50% )
EPS Correlation: -19.39 | EPS CAGR: -5.38% | SUE: 0.0 | # QB: 0
Revenue Correlation: 52.83 | Revenue CAGR: 8.97% | SUE: N/A | # QB: 0
EPS current Quarter (2026-03-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2025-12-31): EPS=2.94 | Chg30d=+2.36% | Revisions=+25% | GrowthEPS=-12.3% | GrowthRev=-16.8%
EPS next Year (2026-12-31): EPS=3.16 | Chg30d=-0.31% | Revisions=-17% | GrowthEPS=+2.5% | GrowthRev=+2.3%
[Analyst] Revisions Ratio: +0% (up=2, down=2)